Axillary Lymph Node Metastasis from Thyroid Malignancy: Unusual Presentation with Ominous Implications

Norman Oneil Machado1*, Pradeep J. Chopra1, Zaid R. Raouf1, Naveed J. Khatib1 and Sinnakirouchenan2

1Department of Surgery, Sultan Qaboos University Hospital, Oman.
2Department of Anesthesiology, Sultan Qaboos University Hospital, Oman.

Authors’ contributions

This work was carried out in collaboration between all authors. Author NOM designed the study, and wrote the final draft of the manuscript. Authors PJC, ZRR, NJK and Sinnakirouchenan managed the literature searches and critically reviewed the manuscript. All authors read and approved the final manuscript.

ABSTRACT

Lymph node metastases to cervical group of nodes occur frequently in well-differentiated thyroid carcinoma. Metastasis to axillary lymph nodes however, is exceptional, leading to diagnostic and management dilemma. While presenting a case of thyroid malignancy with axillary lymph node metastasis, the literature is reviewed for similar cases to analyze their clinico-pathological features, investigations, management and outcome. Fifteen cases have been reported so far. Majority of these patients were female (male: female ratio 6:9) and their mean age was 54.5 years. Axillary lymph node metastases occurred concurrently or as recurrent disease after initial treatment of primary disease in about equal number of these patients. The predominant histological type was papillary carcinoma and 83.3% of these were poorly differentiated. Visceral metastases to lungs and bones were often seen. Despite treating these patients with thyroidectomy, lymph node clearance and adjuvant therapy, 40% of them died; some within one year and among the 60% who were alive, 30% still had active disease.

Conclusion: Axillary lymph node metastasis from thyroid cancer, even though rare should be considered in the differential diagnosis in patients presenting with axillary mass and thyroid malignancy. Based on the limited number of cases reported in the

*Corresponding author: Email: oneilnorman@gmail.com;
literature it appears that it is generally a manifestation of the aggressive nature of this tumor with overall poor outcome.

Keywords: Axillary metastasis; thyroid malignancy; thyroidectomy; lymph node dissection.

1. INTRODUCTION

Well-differentiated thyroid cancer is generally considered as an indolent neoplasm associated with low mortality. Metastases to regional lymph nodes in the neck are often encountered [1,2]. However, some of these tumors (10 to 25%) are aggressive in nature and may present with distant metastasis to lung and bone and spread to extra-cervical group of lymph nodes, including those in the mediastinum [2,3]. The involvement of axillary lymph nodes however is extremely rare presenting with diagnostic and management challenge. We present here a case of thyroid malignancy manifesting with axillary lymph node metastases. From review of literature, 15 similar cases were found, which have been analyzed with regards to their presentation, pathology, management and outcome [4-16].

2. CASE REPORT

A 76 year old male patient was referred to us for management of bilateral cervical and left axillary lymph node enlargement. Seven years ago, he had undergone total thyroidectomy with central node clearance in another hospital, which was reported as well differentiated papillary carcinoma with lymph node metastases. A year later he developed cervical lymphadenopathy for which he received four ablative doses of radioiodine (the response was only modest if any) before he was referred to us. However the number and size of his lymph nodes gradually increased and so did his serum levels of thyroglobulin (Tg). His voice became hoarse. Examination revealed multiple bilateral cervical lymphadenopathy (Fig. 1). The nodes were hard and few of them fixed, size ranging from 1 to 3 cms. He also had enlarged nodes in his left axilla with similar characteristics (Fig. 2). Laryngoscopy showed the left vocal cord fixed in paramedian position. Serum Tg level was 8814 ug/L (0-35). CT scan disclosed bilateral cervical lymphadenopathy at level II, III & IV, along with enlarged mediastinal and left axillary lymph nodes (Fig. 3). Fine needle aspiration cytology (FNAC) carried out on the cervical and axillary lymph nodes, confirmed metastatic papillary carcinoma of thyroid. The radioactive iodine whole body scan revealed no other metastases and was not picked by the enlarged lymph nodes. However CT scan of lung revealed 2 lesions suggestive of metastasis in right lung. The patient underwent bilateral functional neck dissection and axillary lymph node clearance. Histology confirmed metastatic papillary carcinoma of both the cervical and axillary lymph nodes. The nodes in the neck were twelve on right side and nine on left side with significant matting of nodes. There was extracapsular extension of the nodes on both sides and with complete replacement of the node by the tumour in most of them (Fig. 4 and Fig. 5). The axillary nodes were six in number showing similar features of matting and extracapsular involvement. In the postoperative period the serum Tg levels dropped from 8814 to 444 ug/L. In view of the persistent high level of Tg even though markedly reduced, it appeared that the patient had residual disease probably in mediastinal nodes and lung metastasis. He then received Sorafenib (tyrosine protein kinase inhibitor) 400 mg bid and suppressive dose of Thyroxine 150 ugm.
Fig. 1. Bilateral cervical lymphadenopathy seen

Fig. 2. Large left axillary lymphadenopathy seen
Fig. 3. CT scans revealing bilateral cervical and left side axillary nodal metastasis

Fig. 4. H & E stain slide at 10 magnifications showing the lymph node is totally replaced by neoplastic process arranged in papillary structures

Fig. 5. H & E stain slide at 20 magnifications showing a papillary structure lined by columnar cells with enlarged overlapping optically clear nuclei showing longitudinal grooves
2. DISCUSSION

Lymph node metastases, particularly to the cervical group, are often seen in patients with thyroid malignancy, particularly in papillary thyroid cancer (PTC) [1-3,17]. In patients with PTC who have undergone prophylactic neck dissection, micro-metastases have been found in up to 90% of the cases [17]. Lymph nodal metastases have been associated with an increase in recurrence rate and may impact negatively on survival as well [2,18]. The lymphatic drainage pattern of the thyroid gland is uniform and consistent, allowing the pattern of metastatic spread to be relatively predictable. Overall the probability of nodal metastasis in PTC has been reported in the range of 30-90% with an average of 60% [18,19].

The initial nodal spread from PTC, almost always occurs in the central compartment of the ipsilateral neck, in the paratracheal and pretracheal lymph nodes, and in level VI [20]. In the absence of central disease, cases of macroscopic skip metastasis to lateral compartment of the neck are exceedingly uncommon [20]. However, microscopic skipping of central compartment nodes has been reported to occur in 19.7% of the cases [21]. Spread of PTC to nodes in submental and submandibular nodes (level 1) is so rare that they are not included in routine lymph nodal dissection [20]. However for tumors originating from the upper thyroid pole, the first nodal basin is not invariably the central compartment (as for primaries arising from the inferior thyroid pole) but often the upper part of the ipsilateral lateral compartment. Lymph node dissection of the first basin may differ depending on the location of the primary tumor. Involvement of the contralateral lateral compartment is seen in PTC with extensive central compartment involvement [20]. The involvement of axillary lymph nodes in thyroid malignancy is however exceptional [4-16].

2.1 Axillary Lymph Node Metastases

2.1.1 Pathogenesis of spread

The communication between cervical and axillary lymphatics has been described in the past [22]; however the physiological flow is generally centripetal to the jugulo-subclavian junction [5,7,8]. The cervical lymphatics are also in communication with mediastinal lymph nodes and consequently mediastinal lymph nodes are sometimes involved in thyroid malignancy [8,15].

Metastases to axillary lymph nodes are however exceedingly rare due to the centripetal flow. This centripetal flow can however be altered under certain circumstances; namely blockage of lymphatic flow [23,24] due to involvement by carcinoma of sentinel nodes around the lymphatic terminus in the jugulosubclavian confluence. The retrograde spread that follows occurs along the transverse cervical lymph node in the supra-clavicular region. Their retrograde pathway of lymphatic drainage can ultimately lead to axillary lymph node metastases. This is supported by the observation that axillary node metastases are found at autopsy in 2 to 9% of patients who have died of other head and neck cancer [23,24]. Even though the predominant cause for altered lymphatic flow is the blockage of it by metastasis, this could also be the outcome of alteration in lymphatics caused by fibrosis at the subclavian junction following surgical manipulation or radiotherapy. Some are also of the view, that in a small number of patients, axillary nodes could be involved due to haematogenous spread from thyroid malignancy [9,23].
2.1.2 Manifestation

The axillary metastases either present concurrently along with thyroid lesion and cervical lymph node metastases, or years later as a mass in the axilla, after the initial management of thyroid tumor and cervical lymph nodal metastases [4-16]. A significant number of these patients could have concurrent visceral metastasis, predominately to lung, and often to bone and liver [4,8,11,13]. In patients where the axillary node mass is the predominant presentation, evaluation of the neck for thyroid malignancy should be carried out after ruling out initially the possibility of metastases from the more common primary tumors like breast malignancy.

2.1.3 Risk factors for nodal metastasis

Factors that increase the probability of patients having lymphatic metastasis include; age, gender, size of the primary tumors and oncogene expression [12,25]. PTC in pediatric age group has a clinical incidence of lymph node metastases of 80% and in patients above 60 years these are reported to be higher than in midlife. Histological features that seem to predict lymph node metastases are vascular invasion and extra-capsular involvement [1,2].

Several oncogenes assessed histologically in PTC, including p53 and BRAF have been associated with poor prognosis and higher probability of lymph node spread [26]. In one of the reports in patient with axillary lymph node metastases, the positive cell rates of proliferating cell nuclear antigen and Ki-67 were higher in recurrent lymph nodes than in primary tumor itself, suggesting increased cell proliferation in the recurrent lymph nodes [10].

2.1.4 Risk factors for visceral metastasis

Visceral metastasis to bone, lung, liver, brain and skin have been observed in 9% of patients in one of the large series of 972 patients with PTC [28]. A correlation has been observed between the number of lymph nodes and distant metastasis, with more than 20 lymph nodes having a specificity of 90.8% and a negative predictive value of 92.7%. However the sensitivity and positive predictive value were low (27.6 and 22.9%) [28]. On multivariate logistic regression, 1-5,6-10, and 11-20 involved lymph nodes denoted a moderate risk of lung metastasis (odds ratio (OR), 9.9,10.6 and 13.8; P ≤ 0.004), whereas more than 20 involved nodes indicated a high risk of lung metastasis[OR, 25.0;P<0.001]. Mediastinal lymph nodes carried a moderate risk of lung metastasis (OR,7.5;P=0.001) [28].

2.1.5 Management

The primary modality of treatment of PTC with lymph node metastasis remains surgical and comprises of thyroidectomy and lymph node clearance. Total thyroidectomy is indicated in patients <15 years or >45 years, with radiation history, known distant metastasis, bilateral nodularity, extrathyroidal extension, tumour > 4 cms in diameter, cervical lymph nodes with metastasis and aggressive variant (tall cell variant etc). Lymph node clearance is carried out if lymph nodes are palpable or are biopsy positive and would involve clearance of the central neck dissection (level V1) or lateral neck dissection (level 11, level 111, level 1V, including level 1 and Va if clinically involved. Importantly, the use of lymphoscintigraphy during surgery in thyroid cancer has not been found to be useful is assisting the surgeon to determine the sentinel node or ambiguous drainage and hence has been abandoned.
In the postoperative period, investigations are carried out to rule out potential metastasis along the lines discussed below. Following the total or near total thyroidectomy the patient undergoes radiiodine remnant ablation and subsequent hormone therapy.

2.1.6 Investigation work up during follow up

The follow up of patients with PTC following initial thyroidectomy and central compartment node clearance is based on regular clinical evaluation, including palpation of the thyroid bed and careful clinical examination of the regional lymph nodes, usually limited to the cervical area. Investigations such as neck sonography, serum thyroglobulin level (Tg) estimation and diagnostic $^{131}$I- whole body scan (dWBS) are useful in evaluation for recurrence or metastasis [5,8-10,29]. When dWBS is negative inspite of raised levels of Tg, the possibility of visceral and non cervical lymph node metastases including those in the mediastinum and axilla is likely. The detection of metastases in them could be facilitated by investigations that include CT scan, MRI (cerebral/neck/thorax) and bone scintigraphy [4-10]. Exceptionally they have been detected by other investigations. One such reported case, the diagnosis was made after discovery of micro-calcification of axillary mass, while undergoing a screening mammography, [14]. The biopsy of the axillary node confirmed it to be metastasis from thyroid cancer. When the possibility of axillary metastases is likely and the above investigation fails to locate the metastases, $^{18}$F-FDG-PET/CT and $^{131}$I SPECT/CT scans have been found to be useful diagnostic tools, as reiterated in recent reports [30,31]. The sensitivity, specificity and diagnostic accuracy is 65, 55 and 59% for WBS, whereas in $^{18}$F-FDG PET/CT scan it is reported to be 61.98 and 86% respectively[30]. SPECT/CT scan was also found to be superior to WBS and PET/CT scan in patients who have received a single challenge of radio-iodine therapy whereas PET/CT scan was superior to WBS (p=0.005) and SPECT/CT (p=0.013) in patients who received multiple challenges[30]. For organ-based analysis, dWBS was found to be the best detector for lymph node metastasis (72.4%) while PET/CT scan was superior to dWBS for detecting metastases of bone (85.7% vs. 71.4%) and lung (94% vs. 62.7%) [31]. When positive for metastases, it could negatively influence the outcome in such patients. The diagnosis is however finally established by FNAC or trucut biopsy.

2.1.7 Management of patients with raised Tg levels and negative dWBS

There is a general agreement that the most reliable parameter for the detection of tumour recurrence is raised Tg levels [32,33]. Elevated Tg levels, post thyroidectomy and radiiodine remnant ablation, suggest persistence or recurrence of viable tumour tissue [33]. In the last few years questions have been raised as to the value of dWBS compared with $^{131}$I post therapy whole body scan (t WBS) [33-35]. tWBS has been reported to detect new lesions in upto 50% of patients [34,35]. Hence a negative dWBS does not definitely exclude the presence of $^{131}$I avid lesions [33,34]. Empiric radioactive iodine therapy (100-200 mci) might be considered in patients with elevated Tg levels of 10ng /ml or higher after T4 withdrawal, or a level of 5 ng/ml or higher after TSH stimulation, or rising serum Tg levels when imaging (dWBS) has failed to reveal a potential tumour source [36]. If tWBS is negative, no further RAI therapy should be administered (recommendation rating C). If persistent non resectable disease is localized after an empiric dose of RAI and there is objective evidence of significant tumour eradication, then RAI therapy should be repeated until the tumour has been eradicated or tumour no longer responds to treatment [36]. If an empiric dose (100-200 miCu) of RAI fails to localize the persistent disease, than $^{18}$FDG-PET/CT scanning should be considered, especially in patients with estimated serum Tg levels >10-20ng/ml or in those with aggressive histologic variant, in order to localize metastatic
lesions that may require treatment or continued close observation [36]. In patients who are Tg positive, tWBS negative and have disease that is incurable with surgery and is structurally evident or visualized on $^{18}$FDG-PET CT scan, the options of management include thyroid hormone suppression therapy, external beam radiotherapy, chemotherapy, radiofrequency ablation, chemoembolization or monitoring without additional therapy if stable. (recommendation rating C) [36].

3. LITERATURE REVIEW

Review of medline database of articles in English language on axillary metastases from thyroid cancer, revealed a total of 15 cases and include the largest number of cases reported so far [4-16]. Most of the reports in the past, including some recent ones, have reported a maximum of 9 cases.

3.1 Analysis of Results of Literature Review

The male female ratio was 6:9 and the mean age of the patient was 54 years (range 21 to 66) (Table 1). The commonest thyroid cancer among these, 11 (73.3%) was papillary carcinoma. The other histological type that were reported, included one each case of follicular, medullary, sclerosing mucoepidermoid carcinoma with eosinophilia, mucoepidermoid carcinoma, mucin producing adenocarcinoma [11-13,16]. Among the 11 cases where the differentiation details of the tumor were mentioned, in 9 cases (81.8%) the tumors were either poorly differentiated or had variant with poor outcome like the tall cell variant. In 8 (53.3%) of these patients, the axillary lymph nodes manifestation was concurrent with the thyroid malignancy and cervical metastasis. In the rest, the axillary lymph node metastases occurred following the initial management of the thyroid malignancy and cervical node metastasis. The recurrent disease in the axilla occurred in these patients as early as 7 months or as late as 41 years following the initial surgery, with a mean period of 11.7 years (Table 1). In 9 (60%) of these cases the patients also had visceral metastasis, the commonest organ of spread being lung and the bone [4,8,11,13] with an exceptional case of metastasis in the breast [7]. The primary management strategy in these patients was thyroidectomy followed by functional block dissection of cervical nodes and axillary nodes clearance. The adjuvant therapy comprised of radioactive iodine therapy and suppressive dose of thyroxine. Some of the patients in addition received external beam radiotherapy to the neck and in those with visceral metastasis received chemotherapy (Table 1). Among the 10 patients where the outcome was reported, 4 (40%) of these patients died some within one year, 3 (30%) were alive with disease and 3 (30%) were alive being disease free (Table 1). Off late treatment with thyrosine kinase inhibitor has been tried for patients with differentiated thyroid cancer [37]. This has been shown to be useful in patients with progressive radioactive iodine- resistant differentiated thyroid cancer where management options have been limited. Their effectiveness has been reported in patients with widely metastatic progressive differentiated thyroid cancer with most patients achieving stable disease or partial response despite having progressive disease at baseline. The most noticeable response was reported in lung in contrast with minimal changes in nodal metastasis and progressive disease in pleural and non-irradiated bone metastasis suggesting a tissue specific response [37].
| Year  | Author                      | Age yrs | Sex | Histology | Differentiation | Appearance of axillary lymph node | Adjuvant therapy | Metastases | outcome       |
|-------|-----------------------------|---------|-----|-----------|-----------------|-----------------------------------|-----------------|------------|---------------|
| 2012  | Present case                | 71      | M   | Pap.      | Well differentiated | Recurrent 7yrs later concurrent   | RAI              | Lung       | ALD 8 months |
| 2012  | Chiofalo et al.             | 65      | M   | Foll.     | Hurthle cell         | Recurrent-6 years concurrent      | Thy Sup         | Multiple   | ALD 1 yr     |
| 2011  | Krisnamurthy et al.         | 64      | F   | Pap.      | Tall cell variant   | Recurrent-17 years               | Thy Sup         | Breast     | NA            |
| 2009  | Kepenecki                   | 63      | F   | Pap.      | Well Differentiated insular | Recurrent-17 years               | None             | Lung       | ALD 1 yr     |
| 2009  | Angeles-Angelés             | 58      | F   | Pap.      | Insular             | Concurrent                        | RAI              | Lung       | ALD 1 yr     |
| 2007  | Nakayama                    | 21      | M   | Pap.      | Partial poorly      | Concurrent                        | RAI              | Lung       | ALD 1 yr     |
| 2006  | Ers et al.                  | 62      | F   | Pap.      | NA                  | Recurrent-5 years                 | Thy Sup         | Multiple   | Death 8 months |
| 2004  | Koike et al.                | 51      | M   | Pap.      | Partially poor      | Concurrent                        | RAI EBRT Chemotherapy | Lung       | NA            |
| 2004  | Shehadeh et al.             | 38      | F   | SMECE     | NA                 | Concurrent                        | None             | Death      | NA            |
| 2003  | Lal                         | 65      | M   | Pap.      | poorly              | Recurrence-41 years               | NA               | Multiple   | Death         |
| 2003  | Lal                         | 59      | M   | MTC       | poorly              | Concurrent                        | NA               | Multiple   | ALD           |
| 2003  | Lal                         | 45      | M   | Pap.      | poorly              | Concurrent                        | NA               | Multiple   | Death         |
| 2002  | Minagawa et al.             | 52      | M   | MEC       | NA                 | Concurrent                        | Chemotherapy     | Lung vertebra | Death         |
| 1998  | Chen et al.                 | 66      | F   | Pap.      | Well differentiated | Recurrent-7 years                 | Tomoxifen (oestrogen receptor positive) | None | NA           |
| 1996  | Ueda et al.                 | 45      | F   | Pap.      | NA                 | Recurrent-7 years                 | None             | None       | NA            |
| 1993  | Mizukami et al.             | 58      | M   | MAC       | poorly              | Recurrent-7 months                | RAI              | None       | Dis Fr       |
4. CONCLUSION

Axillary lymph node metastases from thyroid cancer are very rare. However it should be considered in the differential diagnosis of axillary masses in the presence of thyroid malignancy. During the follow up in patients with thyroid malignancy, persistent raised serum thyroglobulin level with negative radioactive iodine scan would warrant careful examination for metastasis at other sites including in the axillary nodes. Various diagnostic tools including FDP- PET/CT scan may be useful in doing so. Axillary node metastasis may occur concurrently or manifest as recurrent disease. It however appears that it has an ominous outcome as unfortunately majority of them have other visceral metastasis and two third of them would have succumbed to the disease or are alive with active disease.

CONSENT

All authors declare that written informed consent was obtained from the patient for publication of this case report and accompanying images.

ETHICAL APPROVAL

Not applicable.

ACKNOWLEDGEMENTS

Would like to thank Dr. Asim Qureshi - Consultant pathologist – Sultan Qaboos University Hospital- Muscat- for his contribution on histopathology input and slides.

COMPETING INTERESTS

Would like to declare that there are no competing interests in writing this article.

REFERENCES

1. Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH et al. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. 2010;20(2):14752.
2. de Meer SG, Dauwan M, de Keizer B, Valk GD, BorelRinkes IH, Vriens MR. Not the number but the location of lymph node matters for recurrence rate and disease free survival in patients with differentiated thyroid cancer. World J Surg. 2012; doi. 10.1007/s000268-012-1427-1. Online.
3. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328(8):553-9.
4. Chiofalo MG, Losito NS, Fulciniti F, Setola SV, Tommaselli A, Marone U, et al. Axillary node metastasis from differentiated thyroid carcinoma with Hurthle and signet cell differentiation. A case of disseminated thyroid cancer with peculiar histologic findings. BMC Cancer. 2012;12:55.
5. Krishnamurthy A, Vaidhyanathan A. Axillary lymph node metastasis in papillary carcinoma: report of a case and review of the literature. J Canc Res Ther. 2011;7(2):220-2.
6. Kepenecki I, Demirkan A, Cakmak A, Tug T, Ekinci C. Axillary lymph node metastasis as a late manifestation of papillary carcinoma. Thyroid. 2009;19(4):417-9.
7. Angeles-Angeles A, Chable-Montero F, Martinez-Benitez B, Albores-Saavedra J. Unusual metastases of papillary thyroid carcinoma: Report of 2 cases. Ann Diag Pathol. 2009;13(3):189-96.
8. Nakayama H, Wada N, Masudo Y, Rino Y. Axillary lymph node metastasis from papillary thyroid carcinoma. Report of a case. Surg Today. 2007;37(4):311-5.
9. Ers V, Galant C, Malaise J, Rahier J, Daumerie C. Axillary lymph node metastasis in recurrence of papillary thyroid carcinoma. A case report. Wein Klin Wochenschr. 2006;118:124-7.
10. Koike K, Fujii T, Yanaga H, Nakagawa S, Yokoyama G, Yahara T et al. Axillary lymph node recurrence of papillary thyroid microcarcinoma: report of a case. Surg Today. 2004;34(5):440-3.
11. Shehadeh NJ, Vernick J, Lonardo F, Madan SK, Jacobs JR, Yoo GH, et al. Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: a case report and review of the literature. Am J Otolaryngol. 2004;25(1):48-53.
12. Lal G, Ituarte P, Duh QY, Clark O. The axilla as a rare site of metastatic thyroid cancer with ominous implications (abstract only). 74th Annual meeting of ATA; 2003.
13. Minagawa A, Itakura H, Suzuki H, Yasuda S, Kameyama K, Shimada S et al. A case of primary mucoepidermoid carcinoma of the thyroid: molecular evidence of its origin. Clin Endocrinol. 2002;57(4):551-6.
14. Chen SW, Bennett G, Price J. Axillary lymph node calcification due to metastatic papillary carcinoma. Australas Radiol. 1998;42(3):241-3.
15. Ueda S, Takahashi H, Meite H, Nakata T. A case of axillary lymph nodes recurrence of papillary carcinoma 7 years after the operation. J Jpn Surg Assoc. 1996;57:2934-7.
16. Mizumaki Y, Nakajima H, Annen Y, Michigishi T, Nonomura A, Nakamura S. Mucin producing poorly differentiated adenocarcinoma of the thyroid: A case report. Pathol Res Pract. 1993;189(5):608-12.
17. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and recurrent thyroid cancer. World J Surg. 2002;26:22-8.
18. Mazzafari EL, Hjiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28.
19. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414-24.
20. Gimm O, Rath FW, Dralle H. Pattern of lymph node metastasis in papillary thyroid carcinoma. Br J Surg. 1998;85(2):252-54.
21. Machens A, Holzhausen HJ, Dralle H. Skip metastasis in thyroid cancer leaping the central lymph node compartment. Arch Surg. 2004;139(1):43-5.
22. Rouviere H. Anatomie des lymphatiques de l’homme. Paris:Mason:1932.
23. Kowalski LP. Non cervical lymph node metastasis from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:252-5.
24. Oo AL, Yamaguchi S, Iwaki H, Amagasa T. Axillary nodal metastasis from oral and maxillofacial cancer: a report of 3 cases. J Oral Maxillofac Surg. 2004;62(8):1019-24.
25. Rotstein L. the role of lymphadenectomy in the management of papillary carcinoma of thyroid. J Surg Oncol. 2009;99(4):186-8.
26. Dralle H, Machens A. Surgical management of the lateral neck compartment for metastatic thyroid cancer. Curr Opin Oncol. 2012;25(1):20-6.
27. Baloch LW, Livolsi VA. Pathological diagnosis of papillary thyroid carcinoma: Today and Tomorrow. Expert Rev Mol Diagn. 2005;5(4):573-84.
28. Machens A, Dralle H. Correlation between the number of lymph node metastasis and lung metastasis in papillary thyroid cancer. J Clin Endocrinol Metab. 2012;97(12):4375-82.

29. Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging and positron emission tomography in the assessment of thyroid cancer. Semin in Nucl Med. 2006;36(3):194-205.

30. Oh JR, Byun BH, Hong SP, Chong A, Kim J, Yoo SW, et al. Comparison of $^{131}$I whole body imaging, $^{131}$I SPECT/CT and $^{18}$F-FDG-PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(18):1459-68.

31. Nagamuchi S, Wakamatsu H, Kiyohara S, Nishii R, Mizutani Y, Fujita S, et al. Comparison of diagnostic and prognostic capabilities of $^{18}$F-FDG-PET/CT, $^{131}$I scintigraphy and diffusion weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol. 2011;29(6):413-22.

32. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(4):1433-41.

33. Pace L, Klain M, Albanese C, Salvatore B, Storto G, Sorcielli A, Salvatore M. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging. 2006;33(2):179-83.

34. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78(3):629-34.

35. Lind P. Should high hTg levels in the absence of iodine uptake be treated?. Eur J Nucl Med Mol Imaging. 2003;30(1):157-60.

36. Cooper DS, Doherty GM, Hauger Bryan R, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.

37. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitor for patients with differentiated thyroid cancer: the M.D. Anderson experience. J Clin Endocrinol Metab. 2010;95(6):2588-95.

© 2013 Machado et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.